Predictors of Persistence to Deutetrabenazine Among Patients With Tardive Dyskinesia (TD) and Huntington’s Disease (HD)
Objective: To identify real-world predictors of persistence to deutetrabenazine in patients with TD or HD. Background: Deutetrabenazine is FDA-approved to treat TD in adults and…Evaluation of the QTc prolongation risk of deutetrabenazine
Objective: To assess QTc prolongation risk of deutetrabenazine and its active metabolites by conducting exposure-QTc interval modeling, and to predict QTc prolongation in both CYP2D6…Risk of Tardive Dyskinesia in Patients with Tic Disorders: Preliminary Results
Objective: To determine the relative risk of tardive dyskinesia in patients with tic disorders by comparing three clinical populations: i) patients with tic disorders without…Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria
Objective: To determine the frequency and profile of TS in persons on antipsychotics attending tertiary psychiatry hospitals. Background: The term tardive syndrome (TS) encompasses the…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »